Stock Analysis on Net
Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$22.49

This company has been moved to the archive! The financial data has not been updated since February 15, 2024.

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Paying user area

Try for free

Vertex Pharmaceuticals Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Vertex Pharmaceuticals Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Accounts payable
Product revenue accruals
Payroll and benefits
Research, development and commercial contract costs
Royalty payable
Tax related accruals
Other
Accrued expenses
Milestone payment due to CRISPR
Contract liabilities
Current finance lease liabilities
Current operating lease liabilities
Other
Other current liabilities
Current liabilities
Long-term finance lease liabilities
Long-term operating lease liabilities
Tax-related liabilities
Contingent consideration
Other
Other long-term liabilities
Long-term liabilities
Total liabilities
Preferred stock, $0.01 par value; none issued and outstanding
Common stock, $0.01 par value
Additional paid-in capital
Accumulated other comprehensive income (loss)
Retained earnings (accumulated deficit)
Shareholders’ equity
Total liabilities and shareholders’ equity

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Vertex Pharmaceuticals Inc. current liabilities as a percentage of total liabilities and shareholders’ equity decreased from 2021 to 2022 but then increased from 2022 to 2023 not reaching 2021 level.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Vertex Pharmaceuticals Inc. long-term liabilities as a percentage of total liabilities and shareholders’ equity decreased from 2021 to 2022 and from 2022 to 2023.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Vertex Pharmaceuticals Inc. total liabilities as a percentage of total liabilities and shareholders’ equity decreased from 2021 to 2022 and from 2022 to 2023.
Shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Vertex Pharmaceuticals Inc. shareholders’ equity as a percentage of total liabilities and shareholders’ equity increased from 2021 to 2022 and from 2022 to 2023.